알츠하이머병의 새로운 생물학적 정의: 2018 National Institute on Aging-Alzheimer’s Association Research Framework 소개

키워드

참고문헌 (41)

1. McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
2. Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.270~279 (2011)
3. Sperling RA, "Toward defining the preclinical stages of Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.280~292 (2011)
4. Jack CR, "Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.257~262 (2011)
5. Bateman RJ, "Clinical and biomarker changes in dominantly inherited Alzheimer’s disease", N Engl J Med, 367, pp.795~804 (2012)
6. Fleisher AS, "Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred : a cross-sectional study", JAMA Neurol, 72, pp.316~324 (2015)
7. Villemagne VL, "Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease : a prospective cohort study", Lancet Neurol, 12, pp.357~367 (2013)
8. Villemagne VL, "Tau imaging : early progress and future directions", Lancet Neurol, 14, pp.114~124 (2015)
9. Villemagne VL, "In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease", Eur J Nucl Med Mol Imaging, 41, pp.816~826 (2014)
10. Jack CR, "NIA-AA Research Framework : toward a biological definition of Alzheimer’s disease", Alzheimers Dement, 14, pp.535~562 (2018)
11. Serrano-Pozo A, "Mild to moderate Alzheimer dementia with insufficient neuropathological changes", Ann Neurol, 75, pp.597~601 (2014)
12. Murray ME, "Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics : a retrospective study", Lancet Neurol, 10, pp.785~796 (2011)
13. Jack CR Jr, "A", T, Neurology, pp.2016, 87[DOI]
14. Villain N, "Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease : a voxelwise PiB-PET longitudinal study", Brain, 135, pp.2126~2139 (2012)
15. Visser PJ, "Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study : a prospective cohort study", Lancet Neurol, 8, pp.619~627 (2009)
16. Chhatwal JP, "Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly", Neurology, 87, pp.920~926 (2016)
17. Brier MR, "Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease", Sci Transl Med, 8 (2016)[DOI]
18. Blennow K, "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease", Nat Rev Neurol, 6, pp.131~144 (2010)
19. Besson FL, "Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer’s disease", J Neurosci, 35, pp.10402~10411 (2015)
20. Knopman DS, "Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis", JAMA Neurol, 70, pp.1030~1038 (2013)
21. Montine TJ, "National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease : a practical approach", Acta Neuropathol, 123, pp.1~11 (2012)
22. Hyman BT, "National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease", Alzheimers Dement, 8, pp.1~13 (2012)
23. Jack CR Jr, "An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease", Ann Neurol, 71, pp.765~775 (2012)
24. Gordon BA, "The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging", Brain, 139, pp.2249~2260 (2016)
25. AV1451 tau PET and CSF measures of tau pathology in a clinical sample, "Neurology", 2018, e282~e290, -e290.
26. Landau SM, "Amyloid-β imaging with pittsburgh compound B and florbetapir : comparing radiotracers and quantification methods", J Nucl Med, 54, pp.70~77 (2013)
27. Makaretz SJ, "Flortaucipir tau PET imaging in semantic variant primary progressive aphasia", J Neurol Neurosurg Psychiatry, 89, pp.1024~1031 (2018)
28. -AV-1451(T807)on postmortem brain tissue, "Ann Neurol", 2015, 787~800
29. -AV-1451 imaging in non-Alzheimer tauopathies, "Ann Neurol", 2017, 117~128
30. Hostetler ED, "Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles", J Nucl Med, 57, pp.1599~1606 (2016)
31. Skillbäck T, "Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease : results from the swedish mortality registry", JAMA Neurol, 71, pp.476~483 (2014)
32. Buerger K, "CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease", Brain J Neurol, 129, pp.3035~3041 (2006)
33. Barkhof F, "The significance of medial temporal lobe atrophy : a postmortem MRI study in the very old", Neurology, 69, pp.1521~1527 (2007)
34. van Rossum IA, "Injury markers predict time to dementia in subjects with MCI and amyloid pathology", Neurology, 79, pp.1809~1816 (2012)
35. Roe CM, "Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later", Neurology, 80, pp.1784~1791 (2013)
36. Chételat G, "Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease", Brain, 139, pp.2528~2539 (2016)
37. Gauthier S, "Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration(ATN) : what about the role of vascular changes, inflammation, Lewy body pathology", Transl Neurodegener, 7, pp.12~ (2018)
38. Dubois B, "Advancing research diagnostic criteria for Alzheimer’s disease : the IWG-2 criteria", Lancet Neurol, 13, pp.614~629 (2014)
39. Ovod V, "Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis", Alzheimers Dement, 13, pp.841~849 (2017)
40. Nakamura A, "High performance plasma amyloid-β biomarkers for Alzheimer’s disease", Nature, 554, pp.249~254 (2018)
41. Mattsson N, "Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease", JAMA Neurol, 74, pp.557~566 (2017)

관련 논문AI추천